Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
PointsN Pre-exposure prophylaxis (PrEP) has been demonstrated to be safe and efficacious in clinical trials and emtricitabine/tenofovir was approved by the United States Food and Drug Administration for use as PrEP in 2012.N We report early experiences with PrEP uptake and delivery in three different settings in San Francisco: a PrEP demonstration project in a municipal sexually transmitted diseases (STD) clinic, and two PrEP delivery programs (a private health maintenance organization and an HIV-specific reproductive health program).N Interest in PrEP is high in San Francisco, particularly among men who have sex with men attending the STD clinic, and it is feasible to incorporate PrEP into busy clinical settings.Key next steps for PrEP implementation include increasing PrEP knowledge; expanding PrEP access; combating PrEP stigma; and optimizing interventions to promote PrEP uptake and adherence while reinforcing risk reduction strategies.N PrEP can be an important component of a comprehensive HIV prevention program and complement efforts to increase HIV testing, linkage to care, and early initiation of antiretroviral therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096 · cited 1×
“phylaxis (PrEP) trials of men who have sex with men (MSM) conducted across four continents and serodifferent heterosexual couples and young men and women in sub-Saharan Africa [1–3], the FDA issued the landmark approval of once-daily, coformulated emtricitabine/tenofovir (FTC/ TDF) for HIV prevention in men and women…”
BackgroundSelf-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256 · cited 1×
“cacy [5], the lack of risk compensation in blinded PrEP trials [2,6,7], and the importance of ensuring individuals are”
BackgroundAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996 · cited 1×
“phylaxis (PrEP) trials of men who have sex with men (MSM) conducted across four continents and serodifferent heterosexual couples and young men and women in sub-Saharan Africa [1–3], the FDA issued the landmark approval of once-daily, coformulated emtricitabine/tenofovir (FTC/ TDF) for HIV prevention in men and women…”
BackgroundPreexposure Prophylaxis for HIV Infection among African Women
Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,603 · cited 3×
“Although the FDA approval marks an important milestone in HIV prevention, several factors, including negative results from two recently completed PrEP trials among women in Africa [12,13]; perceived low demand for PrEP [14–17]; and The Health in Action section is a forum for individuals or organizations to highlight t…”
BackgroundChoopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward
Mahajan, A. P., Sayles, J. N., Patel, V. A., Remien, R. H., Sawires, S. R., Ortiz, D. J., Szekeres, G., & Coates, T. J. (2008) · AIDS · doi:10.1097/01.aids.0000327438.13291.62 · Cited by 1,404 · cited 1×
“HIV-related stigma and discrimination have a profoundly negative impact on people living with and at risk for HIV [57], acting as deterrents to HIV-testing, serostatus disclosure, and linkage and retention in care [58].”
BackgroundBannister, S. J. (2009) · Cited by 751
Smith, A. J., Le, B., Finlayson, T., Oster, A. M., & DiNenno, E. A. (2010) · MMWR Morbidity and Mortality Weekly Report · Cited by 432
Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion.
Bernstein, K. T., Marcus, J. L., Nieri, G., Philip, S. S., & Klausner, J. D. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181c3ef29 · Cited by 360 · cited 1×
“3% annual seroconversion rate [35].”
Smith, D. K., Grant, R. M., Weidle, P. J., Lansky, A., Mermin, J., & Fenton, K. A. (2011) · PubMed · Cited by 325
Cited by
Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., Hosek, S., Mosquera, C., Casapia, M., Montoya, O., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70847-3 · Cited by 1,208
Self-citationLiu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., Chege, W., Postle, B. S., Matheson, T., Amico, K. R., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4683 · Cited by 602
Traeger, M. W., Schroeder, S. E., Wright, E. J., Hellard, M. E., Cornelisse, V. J., Doyle, J. S., & Stoové, M. A. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy182 · Cited by 447
“Eleven studies were conducted in the United States, and all but 2 studies were undertaken in high-income countries.”
BackgroundInfluentialPrEP stigma: implicit and explicit drivers of disparity
Golub, S. A. (2018) · Current HIV/AIDS Reports · doi:10.1007/s11904-018-0385-0 · Cited by 383
Calabrese, S. K., & Underhill, K. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302816 · Cited by 313
Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia
Kelley, C. F., Kahle, E., Siegler, A., Sanchez, T., del Rio, C., Sullivan, P. S., & Rosenberg, E. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ664 · Cited by 298
Sevelius, J. M., Keatley, J., Calma, N., & Arnold, E. (2016) · Global Public Health · doi:10.1080/17441692.2016.1154085 · Cited by 283
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
Deutsch, M. B., Glidden, D. V., Sevelius, J., Keatley, J., McMahan, V., Guanira, J., Kallas, E. G., Chariyalertsak, S., & Grant, R. M. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00206-4 · Cited by 268
Koechlin, F. M., Fonner, V. A., Dalglish, S. L., O’Reilly, K. R., Baggaley, R., Grant, R. M., Rodolph, M., Hodges-Mameletzis, I., & Kennedy, C. E. (2017) · AIDS and Behavior · doi:10.1007/s10461-016-1627-z · Cited by 207
Gleason, N., Smith, G., Canning, J. R., George, W. H., Larimer, M. E., Jennings, T. L., Coleman, E., & Miner, M. H. (2023) · AIDS and Behavior · doi:10.1007/s10461-022-03961-6 · Cited by 15
“PrEP was first approved by the FDA in 2012, though uptake was slow in the early years after its introduction [55, 56].”
Background
Metadata
- Authors
- Liu, A., Cohen, S., Follansbee, S., Cohan, D., Weber, S., Sachdev, D., & Buchbinder, S.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-04
- Volume
- 11
- Issue
- 3
- Pages
- e1001613
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2029513457
- Cited by
- 250
- References
- 51
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.